



Fresenius Medical Care

P R E S S R E L E A S E

February 3, 2006
Joachim Weith
Corporate Communications
Tel.: +49-6172-6082101
Fax: +49-6172-6082294
e-mail: pr@fmc-ag.de
www.fmc-ag.com

Successful Conversion Period for Fresenius Medical Care Preference Shares; Approximately 95% of Preference Shares Tendered

(U.S. offer to conclude at midnight EST tonight)

Fresenius Medical Care AG ("the Company") (Frankfurt Stock Exchange: FME, FME3) (NYSE: FMS, FMS-p), the world's largest provider of Dialysis Products and Services, today announced that approximately 95% of all outstanding preference shares have been tendered for conversion into ordinary shares during the 4 week conversion period. This includes American Depositary Shares (ADS), of which roughly 92% of all the outstanding preference ADS have been tendered. The U.S. conversion offer ends tonight at 12.00 midnight EST. The final number of tendered preference shares (including tendered ADSs) is expected to be announced on February 8, 2006.

Ben Lipps, Chief Executive Officer of Fresenius Medical Care, commented: "I am very pleased that approximately 95% of all outstanding preference shares have been tendered. This demonstrates the attractiveness of the conversion offer. With the completion of the conversion we have fulfilled the mandate of the extraordinary shareholder meeting on August 30, 2005. The conversion and the change of the legal form of our Company are major steps towards

enhancing the attractiveness of our shares and in providing flexibility for future growth opportunities for the benefit of all stakeholders.”

Fresenius Medical Care AG is the world's largest, integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1,300,000 individuals worldwide. Through its network of approximately 1,670 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to approximately 130,400 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

For more information about Fresenius Medical Care visit the Company's website at www.fmc-ag.com.

The conversion offer may be made in the United States only by prospectus and ends today at 12:00 midnight EST. Each United States resident preference shareholder of Fresenius Medical Care AG should read the prospectus because it contains important information about the conversion offer. Fresenius Medical Care preference shareholders can obtain the U.S. prospectus and other documents that are filed with the United States Securities and Exchange Commission's website at <http://www.sec.gov>. Preference shareholders may also obtain copies of the prospectus and other documents filed with the Securities and Exchange Commission for free by contacting Fresenius Medical Care.

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG does not undertake any responsibility to update the forward-looking statements in this release.